Search

371 Result(s)
Sort by

Clinical-phase2-trials-NASH-and-obesity

Clinical-phase2-trials-NASH-and-obesity

Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Congress Patient Benefit

Congress Patient Benefit

The participation in scientific congresses is firmly established in the event agenda of any pharmaceutical company. But what is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical represent
Fight against COVID-19 pandemic

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Improving Access to Healthcare

Improving Access to Healthcare

According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
Risk of parasites in dogs

Risk of parasites in dogs

With our Parassess free online tool checker, you can assess the local parasite risks for your dog so you can protect them better.
Phase II trials for patients with bronchiectasis

Phase II trials for patients with bronchiectasis

Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.